Sanguinarine is a novel VEGF inhibitor involved in the suppression of angiogenesis and cell migration

JIA-YING XU¹, QING-HUI MENG², YU CHONG¹, YANG JIAO¹, LIN ZHAO¹, ELIOT M. ROSEN² and SAIJUN FAN¹

¹School of Radiation Medicine and Protection, Medical College of Soochow University, Suzhou, Jiangsu 215123, P.R. China; ²Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA

Received May 9, 2012; Accepted September 26, 2012

DOI: 10.3892/mco.2012.41

Abstract. Vascular endothelial growth factor (VEGF) is a main angiogenic factor which is known to be upregulated in lung cancer. In the present study, it was demonstrated that sanguinarine, an alkaloid obtained from the bloodroot plant, markedly repressed the VEGF-induced tube formation of human microvascular endothelial cells (HMVECs) and the migration of human A549 lung cancer cells. Furthermore, sanguinarine decreased VEGF secretion and expression in HMVECs and A549 lung cancer cells in a dose- and time-dependent manner. Additionally, sanguinarine inhibited the activation of serum starvation- and hypoxia-induced VEGF promoter activity. Sanguinarine also inhibited the VEGF-mediated Akt and p38 activation, as well as VE-cadherin protein phosphorylation. To the best of our knowledge, this is the first study demonstrating that VEGF inhibition appears to be an important mechanism involved in the antiangiogenic and anti-invasive activities of sanguinarine in lung cancer treatment.

Introduction

Vascular endothelial growth factor (VEGF) is one of the most potent and specific regulators in physiological angiogenesis and is an important stimulator of tumor-associated neovascularization (1,2). Angiogenesis also is essential for tumor progression and metastasis. VEGF is expressed in the majority of solid tumors, including lung cancer, and its overexpression is associated with a poor prognosis (3,4). It has been demonstrated that the VEGF pathway can be inhibited by either targeting VEGF directly or inhibiting VEGF receptors. VEGF inhibition is correlated with the suppression of lung cancer growth and angiogenesis (4-7). Therefore, angiogenesis and VEGF are important targets for the treatment of lung cancer.

Materials and methods

Cell lines and reagents. Human microvascular endothelial cells (HMVECs) were cultured in MCDB-131 medium containing basic fibroblast growth factor, heparin, fetal calf serum (FCS), penicillin, streptomycin and amphotericin-B (Sigma-Aldrich, St. Louis, MO, USA) in tissue culture dishes pre-coated with 1.5% gelatin in phosphate-buffered saline (PBS). Human A549 lung cancer cells were obtained from the American Type Culture Collection (Manassas, VA, USA) and routinely cultured in RPMI-1640 medium containing 10% heat-inactivated FCS, penicillin and streptomycin. Recombinant human VEGF was purchased from R&D Systems (Minneapolis, MN, USA). Sanguinarine chloride was purchased from Sigma-Aldrich, dissolved in dimethyl sulfoxide (DMSO) and stored at -20°C.

Tube formation assay. HMVECs from passages 5-8 were seeded on Matrigel-coated 24-well plates to form confluent monolayers. Following the stimulation, of monolayers in medium containing VEGF (30 ng/ml) ± sanguinarine for 48 h, HMVECs were fixed with 0.5 ml of glutaraldehyde/paraformaldehyde mixture (2.5%) and stained with modified May-Gruenwald solution (0.25%). Tubular structure formations were visualized with a Zeiss Axiovert 200 microscope and photomicrographs were documented by a Nikon Coolpix digital camera (Tokyo,
Cells were harvested and lysed on ice for 20 min with ice-cold lysis buffer [150 mM NaCl, 10 mM Tris-HCl (pH 7.5), 1% Triton X-100, 1 mM vanadate, 10 µg/ml leupeptin, 10 µg/ml aprotinin, 1 mM phenylmethylsulfonyl fluoride, 0.36 mM phenanthroline]. The lysates were centrifuged for 10 min at 4°C, and the supernatant was collected. Total protein (100 µg) was boiled in Laemmli sample buffer (125 mM Tris-Cl, pH 6.8, 20% glycerol, 4% SDS, 10% β-mercaptoethanol and 0.00125% bromophenol blue), separated by SDS-PAGE in 10% gel and transferred onto 0.2 µm nitrocellulose membrane by electroblotting. The membrane was blocked with 0.3% bovine serum albumin (BSA) in PBS containing 0.1% Tween-20 and probed with polyclonal antibody against protein kinase C (PKC) for 2 h at room temperature at 4°C. Immunoreactive bands were visualized after an 1-h incubation with horse-radish peroxidase-conjugated anti-mouse antibody, followed by ECL™ Western blot detection system. Anti-pSer473 Akt, anti-Akt, anti-p38 and anti-VE-cadherin antibodies used in the study were purchased from Cell Signaling Technology, Inc. (Beverley, MA, USA). Polyclonal anti-pTyr658 VE-cadherin and anti-p-Tyr731 VE-cadherin were obtained from EMD Millipore Co. (Billerica, MA, USA). Anti-pTyr182 p38 antibody and anti-p-Tyr685 VE-cadherin antibody were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA) and BD Biosciences (San Jose, CA, USA), respectively.

**Results**

**Inhibitory effects of sanguinarine on VEGF-induced angiogenesis and migration.** As shown in Fig. 1A, VEGF-induced tubular structure formation of HMVECs was markedly repressed when HMVECs were cultured in medium supplemented with sanguinarine at 0.25, 0.5, 1.0 and 1.5 µM for 24 h, resulting in an 18, 53, 71 and 82% reduction, respectively. These findings are in agreement with those of previous studies (13-16), suggesting that sanguinarine is a potent inhibitor of VEGF-mediated angiogenesis.

To examine whether or not sanguinarine affects the migration of lung cancer cells, a scratch wound assay was performed. Confluent monolayers of A549 cells were scratch wounded with sterile pipette tips and post-incubated for 24 h in medium containing VEGF ± sanguinarine (0.5 or 1.0 µM; Fig. 1B). In the presence of VEGF, A549 cells rapidly migrated along the edges of the wound and covered the wound, whereas a significant inhibition of cell flattening and spreading was observed in the presence of 0.5 or 1.0 µM sanguinarine. These findings indicate that sanguinarine at non-toxic concentrations significantly suppressed A549 cell migration.

**Inhibition of VEGF secretion by sanguinarine.** Compared to untreated cells, sanguinarine caused a significant dose- and time-dependent inhibition of VEGF secretion in both HMVEC and A549 cells at all the concentrations examined (Fig. 2). For example, 0.25, 0.5 and 1 µM sanguinarine resulted in an ~40, 53 and 80% reduction of VEGF secretion induced by serum starvation in A549 cells at 24 h (P<0.05), while 1 µM sanguinarine induced an ~84, 80, 66, 58 and 60% reduction at 8, 16, 24, 32 and 48 h, respectively (P<0.05).

**Inhibition of VEGF transcripts by sanguinarine.** Exponentially growing A549 cells were cultured in serum-free medium with...
and without 1 µM sanguinarine for 6, 24 or 48 h and harvested for northern blot analysis. As shown in Fig. 3, a single 3.7-kb VEGF message in RNA isolated from A549 cells was detectable. Moreover, a significant time-dependent elevation of VEGF transcripts was observed in A549 cells cultured in serum-free medium (Fig. 3A). For example, an approximately 6- and 9-fold increase was obtained by serum starvation at 24 and 48 h, respectively (P<0.05). Moreover, a further increase of VEGF mRNA was determined when the cells were exposed to 0% O₂ (hypoxia) for 24 h (P<0.05) (Fig. 3B). However, the increased expression of VEGF by serum starvation (P<0.05) and hypoxia (P<0.01) was significantly repressed in the presence of 1 µM sanguinarine.

Repression of VEGF promoter activation by sanguinarine. We also examined the impact of sanguinarine on the VEGF promoter activity stimulated by serum starvation and hypoxia in A549 cells transiently transfected with pGL3-VEGF, a VEGF promoter-luciferase-reporter construct. As expected, a dose-dependent reduction of pGL3-VEGF activation by serum starvation (Fig. 4A) or hypoxia (Fig. 4B) was observed in the presence of sanguinarine. For example, 1.0 µM sanguinarine...
Figure 3. Northern blot analysis of VEGF transcript in human lung cancer cells is shown. (A) A549 cells were cultured in serum-free medium containing 1 µM sanguinarine for the indicated time periods. (B) A549 cells in serum-free medium containing 1 µM sanguinarine were exposed to a normoxic environment consisting of 21% O₂/5% CO₂/remainder N₂ or to hypoxic conditions with 95% N₂/5% CO₂ for 24 h. Total RNA was isolated, and northern blot analysis was performed with 30 µg of RNA/lane. The filter was first probed with a 32P-VEGF probe followed by a 32P-β-actin probe. Representative data are shown from three independent experiments. VEGF, vascular endothelial growth factor.

Figure 4. Sanguinarine inhibits VEGF promoter activity. Exponentially growing A549 cells were transfected with pGL3 (as a negative control) or pGL3-VEGF. (A) Transfected cells at 24 h following transfection were cultured in serum-free medium or (B) were exposed to hypoxic conditions with 95% N₂/5% CO₂ containing various concentrations of sanguinarine. Values are presented as the means ± SEM of six replicate wells from three independent experiments.
resulted in an ~65% reduction of VEGF activation by serum starvation (P<0.05) and an 82% reduction of VEGF activation by hypoxia (P<0.05).

Inhibition of VEGF-mediated protein expression by sanguinarine. As shown in Fig. 5, VEGF (20 min exposure) triggered a significant increase of Akt (Ser473), p38 (Tyr182) and VE-cadherin (Tyr658) phosphorylation, and did not affect the expression levels of VE-cadherin phosphorylation at Tyr685 and Tyr731 sites, Akt, p38 and VE-cadherin protein. However, in the presence of 1.0 µM sanguinarine, the VEGF-mediated phosphorylation activation was markedly reduced or completely inhibited. Similar inhibition findings were also observed in A549 cells treated with 0.5 µM sanguinarine (data not shown).

Discussion

Due to the fact that solid tumors, including lung cancer, are angiogenesis-dependent, the suppression of endothelial cells is likely to result in the inhibition of tumor growth, progression and metastasis. Adhesion molecules, proteases and cytokines are known to be involved in angiogenesis. Among them, the best-studied angiogenic growth factor is VEGF (1,2). VEGF has been demonstrated to bind to the receptor VEGF-R2 and pass the transcriptional signal to the endothelial cells, while also binding to VEGF-R1 to induce endothelial cell-cell interactions and capillary formation. Previous studies demonstrated the effects of sanguinarine on angiogenesis and metastasis. In 2004, Eun and Koh (13) first observed that sanguinarine might inhibit VEGF-induced endothelial cell migration, sprouting and survival in vitro, as well as suppress blood vessel formation in vivo in mouse Matrigel plugs and in the chorioallantoic membrane of the chick embryo model. Subsequently, in their studies, Basini et al (14-16) showed that sanguinarine blocked VEGF-induced vessel growth at 300 nM. Findings of additional studies demonstrated that sanguinarine showed a marked anti-angiogenic activity in a mouse model of melanoma skin cancer (10). Our findings provide further evidence that sanguinarine inhibits VEGF-mediated angiogenesis, as observed by the tube formation assay of HMVECs. In addition, we demonstrated that sanguinarine strongly inhibited the VEGF-induced migration of human A549 lung cancer cells. Sanguinarine-reduced adhesion and invasive activities were also observed in colon cancer cells of NFκB and breast cancer cells (19,20).

In the present study, we also demonstrated that sanguinarine strongly inhibits VEGF protein secretion in conditioned media with serum starvation in either HMVEC or A549 cells. The sanguinarine inhibition of VEGF was also observed at the level of transcriptional regulation, which was manifested by a significant decrease in transcription levels and in VEGF promoter activation by serum starvation and hypoxia. To the best of our knowledge, these findings indicate for the first time that sanguinarine affects VEGF secretion and expression, as well as having a direct impact on VEGF transcription levels and VEGF promoter activation under various types of stress.

These data also showed that the VEGF-mediated phosphorylation activation of Akt (Ser473), p38 (Tyr182) and VE-cadherin (Tyr658), three modulators in the VEGF signaling pathway, was markedly reduced or blocked by sanguinarine. The inhibitory effects of Akt phosphorylation by sanguinarine were also observed by Basini et al (14-16). Those findings suggested that sanguinarine is able to repress the activation of VEGF signal transduction, and that the suppression of Akt (Ser473), p38 (Tyr182) and that VE-cadherin (Tyr658) phosphorylation activation is critical for the inhibition of VEGF-mediated angiogenesis by sanguinarine.
These findings provide a mechanistic basis for the anti-angiogenic and anti-invasive activity of sanguinarine in lung cancer cells, where sanguinarine, a novel VEGF inhibitor, represses VEGF secretion, expression and transcriptional activation. Current studies are focused on the potential applications of sanguinarine alone or in combination with other VEGF inhibiting anticancer drugs for controlling angiogenesis and metastasis of lung and possibly other types of cancer. In addition, investigations are underway as to whether or not other benz[c]phenanthridine alkaloids, such as chelerythrine, chelidonine, sanguilutine and cheliutine, induce the an inhibition of VEGF transcriptional activity and expression, thereby enhancing their antiangiogenic activities.

Acknowledgements

This study was supported by grants from the NNSFC (nos. 81071906 and 81172127), the Program for Scientific Innovation Research of College Graduate in Jiangsu (CX10B-0452); the Outstanding Doctoral Thesis Project of the Soochow University (233209749), the Medical Scientific Research Project of Soochow University (HZ200905) and the Program for Preliminary Scientific Research of Soochow University (SDY2011A45).

References